Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

(2014) Ana Filipa Macedo et al.   BMC Medicine

The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy

(2014) Handrean Soran et al.   CURRENT OPINION IN LIPIDOLOGY

Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)

(2014)   HEART

Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort

(2014) Maryam Kavousi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adverse effects of statins

(2014) Fiona Godlee   BMJ-British Medical Journal

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

(2013) David C. Goff et al.   CIRCULATION

Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile

(2013) Seth S. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report

(2013) Scott M. Grundy et al.   Journal of Clinical Lipidology

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?

(2012) Bob J. H. van Kempen et al.   MEDICAL DECISION MAKING

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk

(2009) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

(2008) A. Pandor et al.   JOURNAL OF INTERNAL MEDICINE